What drives our choices? Evidence, guidelines or habit?

International Journal of Antimicrobial Agents

Volumn 29, Issue SUPPL. 1, 2007, Pages

  Lode, Hartmut ^a   Torres, Antoni ^b   Cockle, Antony ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HOSPITAL CLÍNIC   (Spain)

^c The Lensbury Conference Centre   (United Kingdom)

Author keywords

Chronic obstructive pulmonary disease; Community acquired pneumonia; Evidence based medicine; Guidelines; Respiratory tract infection

Indexed keywords

ANTIBIOTIC AGENT; PLACEBO; TELITHROMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DISEASE EXACERBATION; EVIDENCE BASED MEDICINE; FATALITY; HOSPITAL ADMISSION; HOSPITAL BASED CASE CONTROL STUDY; HOSPITALIZATION; HUMAN; MEDICAL DECISION MAKING; NONHUMAN; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SPUTUM; SYMPTOMATOLOGY;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DECISION MAKING; GUIDELINES; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY TRACT INFECTIONS;

EID: 33847357041     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(07)70006-7     Document Type: Article

References (29)

1. Woodhead M., Blasi F., Ewig S., et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 26 (2005) 1138-1180
2. Jones P., and Agusti A. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J 27 (2006) 822-832
3. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: updated 2005. Available from: http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intId=996 Accessed 22 November 2006
4. Pauwels R., Buist A., Calverley P., Jenkins C., and Hurd S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 163 (2001) 1256-1276
5. Ram F., Rodriguez-Roisin R., Granados-Navarrete A., Garcia-Aymerich J., and Barnes N. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2006) CD004403
6. Stockley R., O'Brien C., Pye A., and Hill S. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 117 (2000) 1638-1645
7. Allegra L., Blasi F., Diano P., et al. Sputum color as a marker of acute bacterial exacerbations of chronic obstructive pulmonary disease. Respir Med 99 (2005) 742-747
8. Anthonisen N., Manfreda J., Warren C., Hershfield E., Harding G., and Nelson N. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 106 (1987) 196-204
9. Soler N., Agusti C., Angrill J., Puig de la Bellacasa J., Miravitlles M., and Torres A. Microbiological validation of Anthonisen criteria in COPD exacerbations: a bronchoscopic study in hospitalized patients. Am J Respir Crit Care Med 169 (2004) A207
10. Connors Jr. A., Dawson N., Thomas C., et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 154 (1996) 959-967
11. Lutfiyya M., Henley E., Chang L., and Reyburn S. Diagnosis and treatment of community-acquired pneumonia. Am Fam Physician 73 (2006) 442-450
12. Gilbert K., and Fine M. Assessing prognosis and predicting patient outcomes in community-acquired pneumonia. Semin Respir Infect 9 (1994) 140-152
13. Smith W., Sumnicht G., Sharpe R., Samuelson D., and Millard F. Granulocyte colony-stimulating factor versus placebo in addition to penicillin G in a randomized blinded study of Gram-negative pneumonia sepsis: analysis of survival and multisystem organ failure. Blood 86 (1995) 1301-1309
14. Hebert J., O'Reilly M., and Gamelli R. Protective effect of recombinant human granulocyte colony-stimulating factor against pneumococcal infections in splenectomized mice. Arch Surg 125 (1990) 1075-1078
15. Cheng A., Stephens D., and Currie B. Granulocyte-Colony Stimulating Factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults. Cochrane Database Syst Rev (2004) CD004400
16. Steinberg K., Hudson L., Goodman R., et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 354 (2006) 1671-1684
17. Dean N., Silver M., Bateman K., James B., Hadlock C., and Hale D. Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. Am J Med 110 (2001) 451-457
18. Dean N., Bateman K., Donnelly S., Silver M., Snow G., and Hale D. Improved clinical outcomes with utilization of a community-acquired pneumonia guideline. Chest 130 (2006) 794-799
19. Menendez R., Torres A., Zalacain R., et al. Guidelines for the treatment of community-acquired pneumonia: predictors of adherence and outcome. Am J Respir Crit Care Med 172 (2005) 757-762
20. British Thoracic Society Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax 56 Suppl iv (2001) iv1-iv64
21. Neill A., Martin I., Weir R., et al. Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 51 (1996) 1010-1016
22. Lim W., Lewis S., and Macfarlane J. Severity prediction rules in community acquired pneumonia: a validation study. Thorax 55 (2000) 219-223
23. Fine M., Auble T., Yealy D., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336 (1997) 243-250
24. Rhew D. Quality indicators for the management of pneumonia in vulnerable elders. Ann Intern Med 135 (2001) 736-743
25. Halm E., Fine M., Marrie T., et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 279 (1998) 1452-1457
26. Menendez R., Torres A., Rodriguez de Castro F., et al. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis 39 (2004) 1783-1790
27. Meehan T., Fine M., Krumholz H., et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 278 (1997) 2080-2084
28. Houck P., Bratzler D., Nsa W., Ma A., and Bartlett J. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 164 (2004) 637-644
29. Ruiz M., Ewig S., Torres A., et al. Severe community-acquired pneumonia. Risk factors and follow-up epidemiology. Am J Respir Crit Care Med 160 (1999) 923-929